Mycapssa, Sandostatin, Sandostatin Lar, SomaKit TOC (octreotide) is a protein pharmaceutical. Octreotide was first approved as Mycapssa on 1988-10-21. It is used to treat acromegaly, adenoma, diarrhea, pancreatic neoplasms, and pituitary neoplasms in the USA. It has been approved in Europe to treat neuroendocrine tumors and radionuclide imaging. The pharmaceutical is active against somatostatin receptor type 2. In addition, it is known to target somatostatin receptor type 3 and somatostatin receptor type 5. Sandostatin's patents are valid until 2036-02-03 (FDA).
|Trade Name||SomaKit TOC|
|Indication||acromegaly, adenoma, diarrhea, neuroendocrine tumors, pancreatic neoplasms, pituitary neoplasms, radionuclide imaging|
|Drug Class||Peptides: inhibition of growth hormone release|